SITC Cancer Immunotherapy Guideline – Non-Small Cell Lung Cancer (NSCLC)

On July 17, 2018, the SITC Cancer Immunotherapy Guidelines Non-Small Cell Lung Cancer (NSCLC)
Subcommittee published a consensus statement specific to the treatment of patients with NSCLC.

This consensus statement consists of evidence-based recommendations from experts in the field for the use and sequencing of immunotherapies including nivolumab, pembrolizumab, atezolizumab and durvalumab. The statement also provides recommendations concerning patient selection, toxicity management and clinical endpoints.

Current Guideline

Published July 17, 2018 in Journal for ImmunoTherapy of Cancer (JITC) as "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)."

view guideline

Webinar-on-Demand

Learn more about immunotherapy treatment standards for non-small cell lung cancer and hear about the Society for Immunotherapy of Cancer’s consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC) in this free one-hour webinar. SITC hosted this session on Thursday, Sept. 13, 2018, featuring members of the Cancer Immunotherapy Guidelines – Non-Small Cell Lung Cancer (NSCLC) Subcommittee.

VIEW WEBINAR-ON-DEMAND

Pocket Guide

Key points from SITC's Cancer Immunotherapy Guidelines have been distilled into Pocket Guides. These condensed, easily accessible versions of the full Cancer Immunotherapy Guidelines are a quick-reference tool available in both digital and print.

Download SITC's Cancer Immunotherapy Guidelines NSCLC Pocket Guide on any desktop or mobile device today.**

*Available only through the Guideline Central App.

ORDER Digital/Print Guides